Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus FOLFOXIRI versus bevacizumab plus FOLFIRI/FOLFOX for first-line metastatic right-sided colon cancer
KCT0003278Phase 2Terminated
- Sponsor
- Boryung
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, fluorouracil, folinic acid, oxaliplatin and irinotecan in colon cancer (2 arms), sponsored by Boryung. Primary endpoint: 6-month progression-free survival rate. Started Jan 2019; status: terminated.
02
Drugs
bevacizumabfluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on KCT0003278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003278.